AG490 is a Janus Kinase 2 (JAK2) inhibitor used for glioma therapy [42], but it also has inhibitory activity toward the epidermal growth factor receptor (EGFR) mediating PI3K/AKT signaling [43]. This evidence concerns the gene AKT1 and central nervous system cancer.